Perspective Therapeutics Inks Clinical Trial Collaboration Agreement With Bristol Myers
(RTTNews) - Radiopharmaceutical company Perspective Therapeutics, Inc. (CATX) announced Tuesday a clinical trial collaboration agreement with Bristol Myers Squibb Co. (BMY) to evaluate the safety and tolerability of Perspective's targeted alpha-particle therapy [212Pb]VMT01 in combination with Bristol Myers Squibb's nivolumab in patients with histologically confirmed melanoma and positive melanocortin 1 receptor (MC1R) imaging scans.
This combination study is an amendment to the Company's ongoing Phase1/2a study of [212Pb]VMT01 in patients with metastatic melanoma. The study has completed enrollment in the first cohort and has commenced dosing in the second cohort.
Under the terms of the collaboration, Perspective will sponsor and fund the combination study and Bristol Myers Squibb will provide nivolumab for use in the study.
I-Mab Inks Partnership With Bristol Myers Squibb To Evaluate Givastomig In Combination Study
Bristol Myers Says Type II Variation Application For Opdivo + Yervoy Granted EMA Validation
Bristol-Myers Squibb Guides FY24 Adj. EPS Above Estimates As Q4 Results Top Estimates - Update
Bristol Myers Squibb To Acquire RayzeBio For $62.50/share In All-cash Deal
Bristol Myers Squibb To Acquire Karuna Therapeutics For $330/share Cash
Avidity Biosciences Inks Global Licensing And Research Collaboration Deal With Bristol Myers Squibb
Bristol-Myers Squibb Boosts FY23 Adj. EPS Outlook As Q3 Adj. EPS Tops Estimates
